Growth hormone secretagogue
CJC-1295 (no DAC) / mod GRF 1-29
The short-acting sister of CJC-1295: a GHRH fragment that produces brief growth-hormone pulses instead of sustained elevation.
What it is
Sold as 'CJC-1295 without DAC' or mod GRF 1-29, this is the first 29 amino acids of growth-hormone-releasing hormone with four substitutions that resist enzyme breakdown. Unlike CJC-1295 with DAC it has no albumin-binding group, so it lasts about half an hour rather than days. It is not approved anywhere and is prohibited in sport; tesamorelin is the related analogue that has been approved, for lipodystrophy.
How it works
- 1
Binds GHRH receptors on the pituitary, triggering growth-hormone release.
- 2
Four substitutions slow enzymatic breakdown, so one dose produces a single clear GH pulse rather than a sustained rise.
- 3
A short pulse is closer to the body's natural rhythm than the week-long elevation produced by the DAC form.
- 4
Often studied alongside a ghrelin-receptor secretagogue such as ipamorelin, because the two act at different points of the same axis.
- 5
Raises IGF-1 secondarily; that is the marker trials measure.
What it's studied for
Reported and studied effects
- A measurable growth-hormone pulse within 15–30 minutes
- Modest IGF-1 increase with repeated use
- Reported better sleep and recovery, based on user accounts rather than trials
- Fluid retention and joint stiffness, as with the growth-hormone class
Research protocol notes
Research context onlyResearch context only — no approved human protocol exists. Human studies used single microgram-per-kilogram doses to characterise GH pulses. Vendor schedules, commonly 100–300 micrograms once or twice daily, sometimes with 200 micrograms of ipamorelin, are community practice rather than clinical evidence.
These figures are described so you can understand what researchers did. They are not a dose, a schedule, or a suggestion — and they are not a substitute for a doctor.
Possible side effects and contraindications
Safety profile
Possible side effects
- Headache, flushing and dizziness shortly after dosing
- Water retention and joint aches
- Numbness or tingling in the hands
- Potential consequences of raised IGF-1 with long-term use
Contraindications and cautions
- Cancer history or active malignancy
- Pregnancy, breastfeeding and childhood
- Diabetes or glucose intolerance
- Prohibited in competitive sport
A side-effect list is never complete, and these are not the only situations that warrant caution. Anything unexpected, or anything you are unsure about, should be discussed with a doctor before use.
Evidence assessment
Its effect on growth-hormone secretion is documented in small human studies, but no trial has tested the body-composition or recovery claims made for it, and it is unapproved.
References
- 01Mod GRF 1-29 (CJC-1295 without DAC) growth hormone studies — PubMed search
- 02GHRH analogues and GH pulsatility — PubMed search
- 03World Anti-Doping Agency — Prohibited List
References link to published literature, regulator pages or literature indexes. Where a link points to a search, it collects the peer-reviewed work on that molecule rather than a single study.
Related
Related peptides
Other entries in Growth hormone secretagogue.
Growth hormone secretagogue
CJC-1295
A modified growth-hormone-releasing hormone analogue whose albumin binding gives it an unusually long action. Studied in small human trials; not an approved medicine.
Growth hormone secretagogue
CJC-1295 (no DAC) + Ipamorelin blend
The classic growth-hormone stack in one vial: a GHRH fragment with a secretagogue, unapproved and prohibited in sport.
Growth hormone secretagogue
GHRP-2 (pralmorelin)
A potent ghrelin-receptor secretagogue used in some countries as a growth-hormone test; sold unapproved for body composition.